FDA Expands CRISPR Gene Therapy Casgevy to Children as Young as 2 with Sickle Cell Disease
FDA approved Casgevy CRISPR gene therapy for children as young as 2 with sickle cell disease on July 1, 2026. Here's what families need to know about this milestone.
Medical Daily ·